In neonatal cholestasis, if the serum gamma glutamyl- transpeptidase (GGT) is more than 600 IU/L the most likely diagnosis is:
**Core Concept**
Gamma glutamyl transpeptidase (GGT) is an enzyme primarily located in the liver and biliary system, playing a crucial role in the transport of amino acids. Elevated serum GGT levels are indicative of bile duct obstruction or cholestasis, as it is released into the bloodstream when bile flow is impaired.
**Why the Correct Answer is Right**
In neonatal cholestasis, a significant elevation of serum GGT (more than 600 IU/L) is highly suggestive of bile duct paucity or Alagille syndrome. This condition is characterized by a reduction in the number of bile ducts within the liver, leading to impaired bile flow and subsequent elevation of GGT. The pathophysiology involves a genetic mutation affecting the JAG1 gene, which is crucial for the development of the bile ducts.
**Why Each Wrong Option is Incorrect**
**Option A:** Biliary atresia is a condition where the bile ducts are absent or blocked, but it typically presents with a more severe elevation of GGT levels (often greater than 1000 IU/L) and is not as strongly associated with a serum GGT level of more than 600 IU/L.
**Option B:** Neonatal hepatitis can cause elevated GGT levels, but the degree of elevation is often less severe compared to bile duct paucity. Moreover, the clinical presentation and laboratory findings of neonatal hepatitis are distinct from those of Alagille syndrome.
**Option C:** Choledochal cysts can cause bile duct obstruction and subsequent elevation of GGT levels, but they are relatively rare in neonates and would not be the most likely diagnosis based solely on a serum GGT level of more than 600 IU/L.
**Clinical Pearl / High-Yield Fact**
In neonatal cholestasis, a high serum GGT level (more than 600 IU/L) is a strong indicator of bile duct paucity or Alagille syndrome, emphasizing the importance of genetic testing for the JAG1 gene mutation in these cases.
**Correct Answer: C. Alagille syndrome.**